Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?
Here is how atai Life Sciences N.V. (ATAI) and Novartis (NVS) have performed compared to their sector so far this year.
atai Life Sciences gains maximum exposure to key psychedelic asset with Beckley Psytech merger
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) stock is poised to move higher following its planned merger with Beckley Psytech, as the combined entity will provide investors with maximum exposure to a promising therapy targeting treatment-resistant depression (TRD), analysts at Jefferies believe. BPL-003, Beckley's intranasal formulation of 5-MeO-DMT, is a short-acting psychedelic with the potential to deliver rapid and durable effects in TRD.
atai Life Sciences and Beckley Psytech to merge in all-share deal, stock pops
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) shares soared before Monday's opening bell after it announced it has inked a definitive agreement to merge with Beckley Psytech, a private clinical-stage biopharmaceutical company developing psychedelic-based therapies, in an all-share transaction valued at $390 million. The merger is contingent upon the achievement of pre-agreed success criteria in Beckley's ongoing Phase 2b trial of BPL-003 (mebufotenin benzoate), the company said.
atai Life Sciences expects key trial data by mid-2025 - ICYMI
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO and co-founder Dr Srinivas Rao talked with Proactive about the company's clinical development progress in 2025, highlighting multiple upcoming trial readouts. Proactive: Hello, you're watching Proactive.
atai Life Sciences N.V. (ATAI) Is Up 18.71% in One Week: What You Should Know
Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors?
atai Life Sciences N.V. (ATAI) Just Flashed Golden Cross Signal: Do You Buy?
Atai Life Sciences N.V. (ATAI) reached a significant support level, and could be a good pick for investors from a technical perspective.
Is atai Life Sciences (ATAI) Outperforming Other Medical Stocks This Year?
Here is how atai Life Sciences N.V. (ATAI) and Cardinal Health (CAH) have performed compared to their sector so far this year.
atai Life Sciences upside highlighted by analysts as more positive data backs Beckley Psytech's depression therapy
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) could see its stock more than double following the release of key trial data later in 2025, according to Jefferies analysts, following another batch of positive clinical trial results from Beckley Psytech's BPL-003 program targeting treatment-resistant depression (TRD). Beckley Psytech's Phase 2a study of BPL-003, an intranasal form of 5-MeO-DMT, showed that a single dose of the therapy along with selective serotonin reuptake inhibitor (SSRI) therapies, produced rapid, robust, and sustained antidepressant effects.
atai Life Sciences announces positive topline data from Phase 2a treatment-resistant depression study
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced positive topline data from Part 2 of Beckley Psytech's Phase 2a study of BPL-003, an intranasal formulation of mebufotenin benzoate, in combination with selective serotonin reuptake inhibitors (SSRIs) for treatment-resistant depression (TRD). The open-label Phase 2a study evaluated the safety, efficacy, and pharmacokinetics of a single dose of BPL-003 in 12 patients with moderate-to-severe depression who had not responded to at least two prior treatments and were taking SSRIs.
atai Life Sciences shares gain momentum ahead of pivotal trial readouts
atai Life Sciences (NASDAQ:ATAI, ETR:9VC)' stock is poised to climb significantly, driven by a series of clinical catalysts this year and next, analysts at Jefferies wrote following the release of the company's first quarter results. The analysts repeated their ‘Buy' rating and $5 price target on atai, which traded up 11.8% at $1.60 on Thursday afternoon.
atai Life Sciences builds clinical momentum in first quarter of 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has kicked off 2025 with strong momentum across its clinical pipeline ahead of expected key data readouts later this year and into 2026. Recent operational highlights include dosing the first patient in a Phase 2 trial of EMP-01 (oral R-MDMA) for social anxiety disorder and continued enrollment in the Elumina study evaluating VLS-01, a buccal film formulation of DMT, in treatment resistant depression.
atai Life Sciences CEO discusses major data readouts expected through 2025 - ICYMI
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO Dr Srinivas Rao talked with Proactive about the company's upcoming clinical milestones and strategic focus in 2025. Rao outlined four major clinical readouts across atai's pipeline of short-duration psychedelics, including updates on VLS-01, BPL-003, RL-007 and EMP-01.
